35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

35Pharma

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience, Inc.

35Pharma | 2,353 followers on LinkedIn. Clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics | 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Cardiometabolic Disease and Obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.

We believe in connecting rigorous science with our innate sense of urgency to rapidly generate breakthrough therapies for patients in need of a better quality of life.

Our beautiful R&amp;D and office facilities are located in the heart of Montreal, Canada, where a diverse team of industry professionals work together to execute on our mission to serve patients in need.

Chief Executive Officer at 35Pharma

Ilia A. Tikhomirov

Biotech Business & Corporate Development executive, IR, PR - passionate about translating science into medicines｜PhD, MBA

Julia Schoelermann

Managing Partner at venBio Partners

Aaron Royston, M.D.

Clinical Research and Development Executive

Monique Champagne

Travelling to ObesityWeek in San Antonio? Join our CSO Maureen O’Connor as she shares exciting pre-clinical data with our novel Activin and GDF inhibitor HS235 in obese HFpEF on Monday, Nov 3rd at 8:30am! Check out the whole press release here: https://lnkd.in/etFwegGu #ObesityWeek #Biotech #heartfailure #obesity #cardiometabolic

We're #hiring a new Senior Clinical Research Associate / Line Manager in Montreal, Quebec. Apply today or share this post with your network.

Joignez-vous à l'équipe! | Join our team! https://lnkd.in/eYXhnJtN

Joignez-vous à l'équipe! https://lnkd.in/enwC33RH

35Pharma Announces Participation at Upcoming Investor Conferences https://lnkd.in/ee6PYaMk

Une excellente #opportunité ! Veuillez le consulter ou le partager avec un collègue...

Rejoindre notre équipe #incroyable aujourd'hui!

Rejoindre notre équipe #incroyable ! Join our #dynamic team!

Metric
Company Name	35	Skye Bioscience, Inc.
Symbol		SKYE
MSH ID	COM:35PHARMA	COM:SKYEBIOSCIENCE
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CA	US
Stage
Employee Count		11
Website	35pharma.com	skyebioscience.com
LinkedIn	35-pharma	skyebioscience
Founders

Metric
Market Cap		107.70M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

35PH

COM:35PHARMA

35Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue